Claims for Patent: 8,173,707

Summary for Patent: 8,173,707

Title:	Ophthalmologic irrigation solutions and method
Abstract:	Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.
Inventor(s):	Demopulos; Gregory A. (Mercer Island, WA), Palmer; Pamela Pierce (San Francisco, CA), Herz; Jeffrey M. (Mill Creek, WA)
Assignee:	Omeros Corporation (Seattle, WA)
Application Number:	12/799,981
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,173,707
Patent Claims:	1. A method for perioperatively inhibiting ocular inflammation and maintaining mydriasis during an intraocular ophthalmologic procedure, comprising irrigating intraocular tissues during an intraocular ophthalmologic procedure with a solution including at least an anti-inflammatory agent and a mydriatic agent in a liquid irrigation carrier, wherein the anti-inflammatory agent comprises ketorolac and the mydriatic agent comprises phenylephrine and each of the agents is included in a therapeutically effective amount for the inhibition of inflammation and maintenance of mydriasis when delivered intraocularly during the intraocular ophthalmologic procedure. 2. The method of claim 1, wherein the ketorolac is included in the solution at a concentration of no more than 100,000 nanomolar and the phenylephrine is included in the solution at a concentration of no more than 500,000 nanomolar. 3. The method of claim 1, wherein the solution is continuously applied to the intraocular tissues during the intraocular procedure. 4. The method of claim 1, wherein the liquid irrigation carrier further comprises an adjuvant selected from electrolytes sufficient to provide a physiological balanced salt solution, a cellular energy source, a buffering agent, a free-radical scavenger and mixtures thereof. 5. The method of claim 4, wherein: the electrolytes, if selected, comprise from 50 to 500 millimolar sodium ions, from 0.1 to 50 millimolar potassium ions, from 0.1 to 5 millimolar calcium ions, from 0.1 to 5 millimolar magnesium ions, from 50 to 500 millimolar chloride ions, and from 0.1 to 10 millimolar phosphate; the buffer, if selected, comprises bicarbonate at a concentration of from 10 to 50 millimolar; the cellular energy source if selected, is selected from dextrose and glucose and is present at a concentration of from 1 to 25 millimolar; and the free-radical scavenger, if selected, comprises glutathione at a concentration of from 0.05 to 5 millimolar. 6. The method of claim 1, wherein the liquid irrigation carrier further comprises electrolytes sufficient to provide a physiological balanced salt solution, a cellular energy source, a buffering agent and a free-radical scavenger. 7. The method of claim 1, wherein the pH of the irrigation solution is between 5.5 and 8.0. 8. A method for perioperatively inhibiting ocular inflammation and maintaining mydriasis during an intraocular ophthalmologic procedure, comprising irrigating intraocular tissues during an intraocular ophthalmologic procedure with a solution including at least an anti-inflammatory agent and a mydriatic agent in a liquid irrigation carrier, wherein the anti-inflammatory agent comprises ketorolac and the mydriatic agent comprises phenylephrine and each of the agents is included in a therapeutically effective amount for the inhibition of inflammation and maintenance of mydriasis when delivered intraocularly during the intraocular ophthalmologic procedure, wherein each of the agents contributes to the maintenance of intraoperative mydriasis by providing for mydriasis or inhibiting miosis. 9. The method of claim 8, wherein the ketorolac is included in the solution at a concentration of no more than 100,000 nanomolar and the phenylephrine is included in the solution at a concentration of no more than 500,000 nanomolar. 10. The method of claim 8, wherein the solution is continuously applied to the intraocular tissues during the intraocular procedure. 11. The method of claim 8, wherein the liquid irrigation carrier further comprises electrolytes sufficient to provide a physiological balanced salt solution.